文献速递造血干细胞移植与细胞治疗

CD47表达增强损害异基因造血干细胞移植后同种反应性T细胞的清除

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT.
PubMed 文献 · Blood · 2025-01-01

本研究探讨CD47在移植物抗宿主病(GVHD)中的作用。分析显示炎症肠道患者回肠T细胞CD47表达上调,GVHD患者胃肠道及GVHD小鼠回肠T细胞亦见CD47上调;活化供者T细胞通过CD47信号抑制抗体依赖性细胞吞噬(ADCP),抗CD47抗体可增强受损的ADCP、提高小鼠胃肠道T细胞吞噬并改善生存,移植CD47缺陷供者T细胞亦改善GVHD评分和生存。结论提示抗CD47治疗可能纠正同种反应性T细胞吞噬受损,有助于缓解移植后炎症。

要点

  • 炎症肠道患者回肠T细胞CD47表达显著上调
  • GVHD患者胃肠道及GVHD小鼠回肠T细胞CD47表达上调
  • 抗CD47抗体增强ADCP、改善小鼠生存,CD47缺陷T细胞移植改善GVHD评分和生存

核心结论

  • CD47上调是GVHD患者中导致同种反应性T细胞吞噬清除受损的关键机制。
  • 本研究提出抗CD47治疗可能纠正受损的同种反应性T细胞吞噬,从而有助于缓解allo-HCT后炎症。

研究设计与样本

  • 研究分析了整体数据集,检测了allo-HCT后胃肠道CD47水平,并在体外和小鼠模型中观察抗CD47抗体及CD47缺陷供者T细胞移植的效果。

主要发现

  • 整体数据集分析显示炎症肠道患者回肠T细胞CD47表达显著上调。
  • GVHD患者胃肠道中CD47表达上调,GVHD小鼠allo-HCT后回肠T细胞上亦鉴定出CD47。
  • 体外实验发现活化供者T细胞通过CD47信号抑制抗体依赖性细胞吞噬(ADCP)。
  • 应用抗CD47抗体显著增强了活化T细胞受损的ADCP。
  • 给予小鼠抗CD47抗体可提高胃肠道T细胞吞噬、诱导免疫抑制反应并改善生存。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) ensues as the most common nonrelapse complication after allogeneic hematopoietic cell transplantation (allo-HCT). A pivotal goal in GVHD management revolves around quelling inflammation. Phagocytic clearance of inflammatory cells contributes substantially to termination of inflammatory processes. Nevertheless, the precise functions of phagocytosis in GVHD remain largely unclear. In this study, we identified the "do not eat me" signal CD47 as a promising target for therapeutic interventions aimed at eradicating alloreactive T cells subsequent to allo-HCT. Analysis of global data sets revealed a remarkable upregulation of CD47 expression on T cells residing in the ileum of patients with inflamed intestine. Building on this finding, we examined CD47 levels in the gastrointestinal tract (GIT) after allo-HCT. Our work not only confirmed upregulated CD47 expression in the GIT of GVHD patients but also identified CD47 on T cells in the ileum of GVHD mice after allo-HCT. Additionally, we found that activated donor T cells suppress antibody-dependent cellular phagocytosis (ADCP) via CD47 signaling in vitro. Application of anti-CD47 antibodies significantly invigorated the impaired ADCP of activated T cells. Administering anti-CD47 antibodies to mice elevated phagocytosis of T cells in the GIT, induced immunosuppressive responses, and improved survival. Finally, transplantation of CD47-deficient donor T cells significantly improved clinical GVHD score with improved survival after allo-HCT. Collectively, our findings illuminate CD47 upregulation as a pivotal mechanism in patients with GVHD, leading to impaired phagocytic clearance of alloreactive T cells. This study proposes that anti-CD47 treatment could rectify the compromised phagocytosis of alloreactive T cells, thereby aiding in the resolution of inflammation after allo-HCT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Flamann C, Shaikh H, Matos C, et al. Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT. Blood. 2025. PMID: 40332470. doi:10.1182/blood.2023023056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。